Delcath Systems’ (DCTH) “Buy” Rating Reaffirmed at HC Wainwright

HC Wainwright restated their buy rating on shares of Delcath Systems (NASDAQ:DCTH) in a research report released on Monday morning,Benzinga reports. They currently have a $22.00 target price on the stock.

Several other research firms have also issued reports on DCTH. Stephens restated a “buy” rating on shares of Delcath Systems in a research report on Friday, October 18th. StockNews.com upgraded shares of Delcath Systems from a “sell” rating to a “hold” rating in a research report on Friday, October 25th. Finally, Canaccord Genuity Group restated a “buy” rating and set a $21.00 target price on shares of Delcath Systems in a research report on Friday, October 18th. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $21.50.

Delcath Systems Stock Performance

Shares of DCTH opened at $9.92 on Monday. Delcath Systems has a 52 week low of $2.25 and a 52 week high of $12.88. The company’s 50 day moving average price is $9.76 and its 200 day moving average price is $8.40. The company has a market capitalization of $275.68 million, a PE ratio of -7.38 and a beta of 0.75.

Institutional Investors Weigh In On Delcath Systems

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Riverwater Partners LLC purchased a new position in Delcath Systems in the third quarter valued at about $161,000. Cubist Systematic Strategies LLC purchased a new position in Delcath Systems in the second quarter valued at approximately $370,000. Levin Capital Strategies L.P. grew its holdings in Delcath Systems by 12.2% during the first quarter. Levin Capital Strategies L.P. now owns 54,969 shares of the company’s stock valued at $262,000 after purchasing an additional 5,969 shares during the period. Renaissance Technologies LLC purchased a new stake in Delcath Systems in the second quarter worth $694,000. Finally, Principal Financial Group Inc. bought a new stake in shares of Delcath Systems in the third quarter valued at $808,000. 61.12% of the stock is owned by hedge funds and other institutional investors.

Delcath Systems Company Profile

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company’s lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.